Why Am I Not Losing Weight on Zepbound?

Why am I not losing weight on Zepbound? The Zepbound label reports weight loss at week 72, it differed by dose and by person, and the label opens with four weeks at a starting dose. A wide gap from the average is part of what the trial recorded, so a result below it is not proof that the medicine is failing. The tables below show how wide the spread was at week 72, so you can place your own result and raise it with your prescriber.

In short

• The Zepbound label starts treatment with four weeks of 2.5 mg weekly, an initiation dose, before the first 5 mg step.
• The Zepbound label reports mean weight loss at week 72 of 15.0%, 19.5% and 20.9% for the 5, 10 and 15 mg arms of SURMOUNT-1.
• The same label table implies 9.1% to 14.9% of treated participants had not reached 5% loss by week 72.

Why am I not losing weight on Zepbound?

Not losing weight on Zepbound can reflect timing, dose step and the spread between people, and the trial data speaks to all three. Timing comes first. The SURMOUNT-1 trial ran 72 weeks and included a 20-week dose-escalation period, so the early weeks were not spent at the doses behind the headline averages.

The averages also hide a spread. The Zepbound label reports the share of participants reaching 5%, 10%, 15% and 20% weight loss, and no dose arm reached 100% at any of them.

Finally, the figures describe one group: 2,539 adults with a BMI of 30 or more, or 27 or more with a weight-related complication, without type 2 diabetes. Your course may differ. This guide describes the trial and cannot say why your weight is where it is. Your prescriber can look at your whole picture.

How long does Zepbound take to start working?

The Zepbound label's weight tables report results at week 72, not week by week, so no single start date for weight loss can be read from them. What the label does give is a schedule of dose steps, and that sets the timeline. This is the label's schedule for weight management:

• Start at 2.5 mg once weekly for 4 weeks. The label calls this an initiation dose, not a maintenance dose.
• Move to 5 mg at week 4.
• Increase in 2.5 mg steps, each after at least 4 weeks on the current dose, up to a maximum of 15 mg weekly.
• Maintenance doses for weight management are 5, 10 or 15 mg weekly.

This is the label's timeline, not a plan to follow. The prescriber decides whether and when any step happens.

The arithmetic shows how long the steps take. Reaching 15 mg in 2.5 mg steps passes five stages (2.5, 5, 7.5, 10 and 12.5 mg), each at least 4 weeks long. Five stages of 4 weeks is 20 weeks, which matches the trial's 20-week escalation period.

The label gives tirzepatide a half-life of approximately 5 days, so each weekly dose adds to what remains from the last. The guide on how long Ozempic stays in your system has a week-by-week decay table beside tirzepatide's. The half-life calculator can estimate how much tirzepatide is still active from your own doses, and it never suggests a dose.

How much weight did people lose in the trial, and how much did it vary?

In SURMOUNT-1, as tabulated in the Zepbound label, the share of people reaching each weight-loss threshold at week 72 rose with dose, and no arm reached everyone. The groups held 643 people on placebo, 630 at 5 mg, 636 at 10 mg and 630 at 15 mg. All were adults without type 2 diabetes, treated once weekly for 72 weeks.

The last row is derived: 100 minus 85.1 is 14.9 at 5 mg, 100 minus 88.9 is 11.1 at 10 mg, and 100 minus 90.9 is 9.1 at 15 mg.

Reading across shows the spread. At 5 mg, 85.1% reached 5% loss and 48.0% reached 15%, so 37.1% (85.1 minus 48.0) finished between those marks. These are shares of a trial group, not predictions for one person.

Does the dose change how much weight comes off?

In the Zepbound label's SURMOUNT-1 results, mean weight loss at week 72 rose with dose: 3.1% on placebo, 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg.

1. Placebo3.1%
2. 5 mg15%
3. 10 mg19.5%
4. 15 mg20.9%

The numbers in this chart

	Mean weight loss
Placebo	3.1%
5 mg	15%
10 mg	19.5%
15 mg	20.9%

Zepbound prescribing information, Section 14.1, Table 2

The step from 5 mg to 10 mg added 4.5 points (19.5 minus 15.0). The step from 10 mg to 15 mg added 1.4 points (20.9 minus 19.5). These are group means, and the label's table cannot say how any one person would respond.

A person at 10 mg who has not reached 5% loss sits among the 11.1% in the table above. That is a documented part of the spread, though it is a reason to talk with a prescriber and not a verdict.

The label's second study enrolled adults with type 2 diabetes. Mean loss at week 72 was 3.2% on placebo, 12.8% at 10 mg and 14.7% at 15 mg. A different group gives different averages, so keep every figure tied to its population. Any dose change is the prescriber's decision.

What is a weight loss plateau, and does the trial data show one?

A weight loss plateau is a stretch where weight stops falling for a while, and the label's tables report week-72 endpoints, so they cannot show when or whether one happens for a single person. What they do show is where groups ended up, and that was far apart.

At 10 mg, 78.1% reached 10% loss but 50.1% reached 20%. That leaves 28.0% (78.1 minus 50.1) who finished between those marks. People on the same dose finished at different weight-loss levels by week 72.

The schedule adds a second point. Reaching 15 mg takes at least 20 weeks of steps, so a reading at week 8 and a reading at week 40 are taken under different dose conditions. Comparing them is not a like-for-like test.

A flat scale for some weeks is a pattern worth logging and raising. Your prescriber can say whether it fits what they would expect for you.

What side effects and warning signs should prompt a call to a doctor?

The Zepbound label lists nausea, diarrhea, vomiting and constipation as the most common adverse reactions, and it also gives warning signs that need medical care. In the pooled weight-management trials, nausea affected 8% on placebo, 25% at 5 mg, 29% at 10 mg and 28% at 15 mg. Vomiting affected 2%, 8%, 11% and 13%.

Contact a doctor or emergency care for any of these signs, as the label describes them:

• Persistent or severe abdominal pain, sometimes spreading to the back, with or without vomiting. The label says to evaluate for pancreatitis and to discontinue Zepbound if it is confirmed.
• Severe or persistent vomiting or diarrhea with signs of dehydration, which the label links to kidney problems.
• Gallbladder symptoms such as pain in the upper right abdomen, fever or yellowing of the skin.
• Signs of a serious allergic reaction.
• A lump in the neck or trouble swallowing.

The last sign relates to the boxed warning. Tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it does in humans. It is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Tell your prescriber about that history.

What quietly misleads when you read your own scale?

Several habits can mislead when a result is read against the trial figures. These are the ones the figures expose.

• Compare like with like. A week-8 weight against a week-72 average sets different dose stages side by side.
• Keep the population in view. The 19.5% and 20.9% means are for adults without type 2 diabetes. The diabetes study gave 12.8% and 14.7%.
• Read averages as averages. A mean of 20.9% at 15 mg sits beside 56.7% of people reaching 20%, which means 43.3% did not.
• Do not treat the threshold rows as a pass mark. The table reports shares reaching each level. It sets no line between a good and a poor response.
• Leave dose decisions with your prescriber. The escalation steps are a timeline. They are not a lever to pull for a stalled week.
• Judge a trend over weeks, not a single reading. The label tables give week 72 only, so one day's weight cannot be matched to them.

How can Dose & Lose help you see your own pattern?

Dose & Lose is a tracking app that keeps doses, weight, protein, water and side effects in one place, so your own pattern sits next to the label's timeline. You log each dose with its date and time, log weight whenever you like, and see a progress chart from a week to a year. You rate symptoms from 0 to 10 and view them beside your doses.

It also draws an estimate of medication level from your logged doses, shown over 7, 30 or 90 days. That is an estimate, not a lab value. The app does not prescribe, give dosing advice, measure anything in your body or tell you whether you are a responder.

You can log weight, doses and side effects together in the app.

Frequently asked questions

Is it normal to see no weight loss in the first few weeks on Zepbound?

The label does not report early weight change, so it cannot say. It starts with four weeks at 2.5 mg weekly, an initiation dose, not a maintenance dose. Its tables report week 72. If you are concerned, share your logged weights with your prescriber.

Does everyone lose weight on Zepbound?

No, not to the same degree. In the SURMOUNT-1 table in the Zepbound label, 9.1% of people on 15 mg and 14.9% on 5 mg had not reached 5% weight loss by week 72 (100 minus 90.9 and 100 minus 85.1). The table sets no pass mark, so discuss your result with your prescriber.

Why did I lose weight at first and then stop?

The label's tables cannot say, because they report week 72 and not the path to it. The label's schedule takes at least 20 weeks to reach 15 mg, so conditions change along the way. Log your weight, doses and symptoms, and bring the record to your prescriber.

What is the difference between Zepbound and Mounjaro?

Both contain tirzepatide, but their US labels differ in use: Zepbound is labelled for weight management (and obstructive sleep apnea in adults with obesity) and Mounjaro for type 2 diabetes. This article's figures come from the Zepbound label and its study populations. Mounjaro label figures should not be swapped in. Your prescriber explains which applies to you.

Sources

• Zepbound prescribing information, DailyMed: escalation schedule, week-72 weight tables, adverse reactions and warnings.
• Jastreboff et al., SURMOUNT-1, NEJM 2022, PubMed 35658024: trial population and 72-week placebo-controlled design.
• Read how Dose & Lose sources and checks the figures in its guides.

Published by Petros IT Solutions SRL, written by the Dose & Lose Editorial Team. Corrections: office@doseandlose.com.